Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose. [Yahoo! Finance]
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Guggenheim.
Immunovant, Inc. (NASDAQ: IMVT) had its price target lowered by analysts at Bank of America Co. from $38.00 to $33.00. They now have a "buy" rating on the stock.
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)